HCV Care in Unique Patient Populations

Slides:



Advertisements
Similar presentations
Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.
Advertisements

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1 Phase 3 Treatment Naïve Source: Afdhal N, et al. N.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.
Phase 3 Treatment Naïve and Treatment Experienced Renal Disease
Hepatitis web study Hepatitis web study Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1 LONESTAR Trial Phase 2a Treatment Naïve and Treatment Experienced Source:
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in Sofosbuvir-Experienced HCV GT1 Retreatment of Sofosbuvir Failures Phase 2 Treatment.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 5 or 6 Robert G. Gish MD Staff Physician, Stanford University.
Hepatitis web study Hepatitis web study Sofosbuvir ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced Source: Gilead.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial Phase 3 Treatment Naïve and Treatment Experienced.
Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.
ELPA Symposium Compassionate Use in Hepatitis C Saving lives of patients who cannot wait Thomas Berg Section of Hepatology Clinic for Gastroenterology.
Daniel Dhumeaux, Henri Mondor hospital Créteil, France HCV compassionate use programme The French experience Amsterdam, April.
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Phase 3 Treatment Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced
Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease EXPEDITION-4
Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3
Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.
EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
Design Randomisation 1 : 1 Open-label W16 W24 > 18 years
Phase 3 Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced
Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1b TURQUOISE-III
Future Trials of Hepatitis C Therapy in the HIV Co-infected
Phase 2 Treatment Naïve HIV Coinfection
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Starting Strong: Initial Evaluation of the Patient With HCV
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present HCV Guidance: Recommendations for Testing,
Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.
Case 53-year-old Black Man
Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic.
Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE
Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.
HCV Protease Inhibitors in Clinical Practice
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
New Agents, New Regimens, New Strategies
Care of the Treatment-naive Patient With HCV/HIV Coinfection
Phase 3 Treatment-Naïve and Treatment-Experienced
Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study
Volume 59, Issue 4, Pages (October 2013)
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Phase 2 Treatment Naïve and Treatment Experienced
Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3
Phase 2b Treatment Naïve and Treatment Experienced
Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.
Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and.
Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection
Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection
Management of cirrhosis due to chronic hepatitis C
HCV Protease Inhibitors in Clinical Practice
Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.
Martina Gambato, Sabela Lens, Miquel Navasa, Xavier Forns 
SOF/VEL in liver transplantation with genotype 1-4 infection
What Does the Future Hold and What Will It Mean for Patients?
REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:
Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Telaprevir in Treatment Experienced GT-1 PROVE3
Phase 3 Treatment-Naïve and Treatment-Experienced
Volume 147, Issue 6, Pages (December 2014)
Johannes Vermehren, James S. Park, Ira M. Jacobson, Stefan Zeuzem 
Presentation transcript:

HCV Care in Unique Patient Populations

Unique HCV Patient Populations Then and Now

What's Unique About HCV-GT3 Infection?

SVR12 in Patients With HCV-GT3 Phase 3 Clinical Trial Results

Treating HCV-GT3 Infection Toward a Ribavirin-Free Regimen for Patients With Compensated Cirrhosis

Treatment of HCV-GT3 Infection

HCV-GT3: Failure to Respond to Treatment With Sofosbuvir Plus Ribavirin Does Retreatment Work?

Cirrhosis: Compensated or Decompensated How Do You Determine?

Severity of Cirrhosis Matters How Do you Classify It?

Decompensated Cirrhosis: Treat Now or After Transplantation?

Use of NS3A Protease Inhibitors Not Recommended in Patients With Decompensated Cirrhosis

Management of Complications of Portal Hypertension

Treatment of Recurrent HCV Infection Posttransplantation

Summary

Abbreviations